Biotechnology

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

TAMPA, Fla., Jan. 7, 2025 /PRNewswire/ -- Concept Medical Inc. , a global leader in innovative drug-delivery technology, proudly reports positive outcomes from theSIRONA (Head-to-Head Comparison ofSIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in th...

2025-01-07 20:14 2685

Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO and SUZHOU, China, Jan. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-01-06 08:00 3937

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-01-03 08:00 9256

Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate

SAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-01-02 07:30 10811

Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study

Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV functional cure DURHAM, N.C. and BEIJING, Dec. 31, ...

2024-12-31 19:10 5082

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase...

2024-12-30 13:28 5997

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx...

2024-12-30 06:00 2983

Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that its Chairman and ...

2024-12-27 09:44 11586

IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune ch...

2024-12-26 17:09 4877

New Generation Centralized Control System Promotes "Integrated Operation Monitoring"

BORTALA, China, Dec. 26, 2024 /PRNewswire/ -- On December 26, personnel at the monitoring operation and maintenance center of the State Grid Bortala Power Supply Company were conducting acceptance testing for the new generation centralized control system. The company is actively promoting the app...

2024-12-26 13:38 2806

Industry Partnership | Basecare Medical Group (2170.HK) and Jinghua Medical Group Sign Strategic Cooperation Agreement

SUZHOU, China, Dec. 25, 2024 /PRNewswire/ -- On December 24, 2024, Basecare Medical Group (2170.HK) held a strategic cooperation signing ceremony with Jinghua Medical Group inShenyang. Basecare Medical possesses a comprehensive technological platform covering andrology, embryo culture, genetics, ...

2024-12-25 11:03 5656

European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan

HEIDELBERG, Germany, Dec. 25, 2024 /PRNewswire/ -- European Wellness Biomedical Group (EWBG) has launched a new research initiative focused onKlotho , a protein with transformative potential inlon...

2024-12-25 09:00 5209

Inauguration of MRI Facility and Health Service Initiative at Bhayangkara Kediri Hospital, Featuring DNA Testing Services in Collaboration with Regene Genomics

JAKARTA and KEDIRI, Indonesia, Dec. 24, 2024 /PRNewswire/ -- Bhayangkara Kediri Hospital inaugurated its new MRI service building and laid the cornerstone for a new service facility, marking a significant step forward in enhancing healthcare services in Kediri and surrounding areas.

2024-12-24 12:38 2854

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

* SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process development and clinical translation. * The parti...

2024-12-23 09:00 3374

Macrogen Consortium win tender for National Bio Big Data Project

Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium. SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and arra...

2024-12-23 08:00 3389

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

* Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive$6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. * Patients with relapsed/refractory follicular lympho...

2024-12-19 23:00 2764

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 /PRNewswire/ -- Prenetics' (NASDAQ:PRE) IM8, a...

2024-12-19 21:30 3106

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South,Belgium, facilita...

2024-12-19 17:02 3457

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid bi...

2024-12-19 01:00 3140

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Highlights: * IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 * The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies,...

2024-12-18 10:59 2655
1 ... 29303132333435 ... 186

Week's Top Stories